Bartosz Hudzik/LinkedIn
Feb 11, 2026, 16:08
Bartosz Hudzik: Clinical Trials to Watch in 2026 – A Cardiovascular Lens
Bartosz Hudzik, Editorial Consultant at JACC Case Reports, shared on LinkedIn:
“Clinical trials to watch in 2026 — a cardiovascular lens
Nature Medicine highlights 11 trials poised to shape medicine in 2026. In cardiology, two stand out:
- Ziltivekimab – targeting the IL-6 inflammatory pathway to reduce residual inflammatory risk in atherosclerosis and CKD, moving beyond lipid-only prevention.
- Pelacarsen – a first-in-class antisense therapy for lipoprotein(a), tackling one of the most important genetically driven and previously untreatable CV risk factors.
Both are Phase 3 programs with the potential to redefine precision prevention.
2026 may be the year cardiovascular medicine shifts from risk markers to causal, target-specific therapies.”
More posts featuring Bartosz Hudzik on Hemostasis Today.
-
Aug 21, 2026, 12:57David McIntosh: Why Do Blood Supplies Still Fall Short?
-
Aug 21, 2026, 12:48Joshua Penrod: 35 Years of Progress in Plasma Safety
-
Aug 21, 2026, 12:42Moustafa Abdou: Diagnosis and Management of Pyruvate Kinase Deficiency
-
Aug 21, 2026, 12:38Luluva Ghadiyali: Modern Approaches to Aplastic Anemia
-
Aug 21, 2026, 12:34Kellie Machlus: Animal Models Driving Progress in Thrombosis Research
-
Aug 21, 2026, 12:08Amy Allen Whitfield: Helping to Proceed Bleeding Disorders Care
-
Aug 21, 2026, 11:53Jan Terje Andersen: Harnessing Placental Biology for Therapeutic Engineering
-
Aug 21, 2026, 11:02Severe ITP, Critical Bleeding, and the Challenge of Platelet Testing – RPTH Journal
-
Aug 21, 2026, 10:46Arwa Z. Al-Riyami: Looking Ahead to ISBT Muscat 2029